Strides signs pact with Gilead Sciences to promote HIV drug

New Delhi Drug firm Strides Arcolab on Monday said it has inked a pact with US-based Gilead Sciences to sell low-cost generic versions of latter's HIV medicine ' emtricitabine' in developing countries.

According to the pact, the Indian firm would also promote fixed-dose combinations of emtricitabine. Under the new agreement, Gilead will provide technology transfer for the manufacture of emtricitabine.